TapewireFind a company

person · Reporting owner

ROBIN SHERRINGTON

Disclosed activity across 1 company

Tapewire entity
93145
SEC CIK
0001619962

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Xenon Pharmaceuticals Inc.XENE · Entity 2602EVP, Strategy & InnovationMarch 11, 2024March 12, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Xenon Pharmaceuticals Inc.

Report date March 11, 2024 · Filed March 12, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37 · Expires 2034-03-10Direct65,000 Reported balance After 2024-03-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-03-11 · Grant · Acquired 65,000 · Balance 65,000

F1: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 11, 2024 Filed Mar 12, 2024 22:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $44.37 $0.00
Disclosure

SEC source: 0000950170-24-030233 · ownership.xml · derivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Shares · 65,000 shares

Expires 2034-03-10

F1 · derivative.exercise_date: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 22:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 7,407 $0.00 Strike: $9.85 $0.00
Disclosure

SEC source: 0000950170-24-028795 · ownership.xml · derivative · entry 8

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 7,407 shares

Expires 2024-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 22:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 1,234 $0.00 Strike: $9.85 $0.00
Disclosure

SEC source: 0000950170-24-028795 · ownership.xml · derivative · entry 7

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 1,234 shares

Expires 2024-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 22:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 6,118 $46.30 $283,263.40
Disclosure

SEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 6

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,398

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 22:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 1,019 $46.15 $47,026.85
Disclosure

SEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 5

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,516

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 22:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,289 $45.96 $59,242.44
Disclosure

SEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 4

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,535

F2 · price: Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 22:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 7,407 $9.85 $72,958.95
Disclosure

SEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 3

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 22:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 215 $45.96 $9,881.40
Disclosure

SEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 2

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,417

F2 · price: Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 22:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 1,234 $9.85 $12,154.90
Disclosure

SEC source: 0000950170-24-028795 · ownership.xml · nonDerivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,632

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
December 29, 2023 Filed Jan 2, 2024 21:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 OtherCommon Shares 8,398 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-000304 · ownership.xml · nonDerivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,398

F1 · kind: Shares were transferred to the Reporting Person's former spouse pursuant to the terms of a settlement agreement dated December 29, 2023 entered into in connection with the dissolution of the Reporting Person's marriage. The Reporting Person no longer reports as beneficially owned any securities owned by his former spouse.

Read SEC document
March 10, 2023 Filed Mar 14, 2023 20:46 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $34.18 $0.00
Disclosure

SEC source: 0001209191-23-018505 · doc4.xml · derivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Shares · 75,000 shares

Expires 2033-03-09

F1 · derivative.exercise_date: Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
September 01, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $4.75 $0.00
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · derivative · entry 11

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 50,000 shares

Expires 2028-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

Read SEC document
September 01, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 8,776 $38.80 $340,508.80
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 8

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,796

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.73 to $38.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
September 01, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 35,103 $38.03 $1,334,967.09
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 7

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,572

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.44 to $38.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
September 01, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 6,121 $38.81 $237,556.01
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 6

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,675

F3 · price: Represents the closing price of the Company's common shares on August 31, 2022 for purposes of net settlement calculations.

Read SEC document
September 01, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 50,000 $4.75 $237,500.00
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 5

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,796

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Options (Right to Buy) · Derivative 5,000 $0.00 Strike: $4.75 $0.00
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · derivative · entry 10

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,000 shares

Expires 2028-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Options (Right to Buy) · Derivative 17,488 $0.00 Strike: $2.67 $0.00
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · derivative · entry 9

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 17,488 shares

Expires 2022-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 21,352 $38.57 $823,546.64
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 4

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,796

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,572 $37.86 $59,515.92
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 3

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,148

F1 · price: Represents the closing price of the Company's common shares on August 30, 2022 for purposes of net settlement calculations.

Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 5,000 $4.75 $23,750.00
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 2

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 17,488 $2.67 $46,692.96
Disclosure

SEC source: 0001209191-22-048508 · doc4.xml · nonDerivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 10, 2022 Filed Mar 14, 2022 20:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $30.01 $0.00
Disclosure

SEC source: 0001209191-22-018463 · doc4.xml · derivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Shares · 75,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 6,172 $0.00 Strike: $3.67 $0.00
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · derivative · entry 9

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 6,172 shares

Expires 2022-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F8 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "Second 2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Second 2012 Vesting Commencement Date

F7 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 1,234 $0.00 Strike: $3.67 $0.00
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · derivative · entry 8

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 1,234 shares

Expires 2022-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F6 · derivative.exercise_date: 1/3 of the shares subject to the Option vested on January 1, 2012 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 4 years.

F7 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 5,000 $30.23 $151,150.00
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 7

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,232

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.15 to $30.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 5,000 $31.05 $155,250.00
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 6

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,232

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.78 to $31.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 5,000 $30.15 $150,750.00
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 5

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,232

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 6,710 $30.56 $205,057.60
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 4

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,232

F2 · price: Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 6,172 $3.67 $22,651.24
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 3

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 696 $31.42 $21,868.32
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 2

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,770

F2 · price: Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 00:35 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 1,234 $3.67 $4,528.78
Disclosure

SEC source: 0001209191-22-017318 · doc4.xml · nonDerivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,466

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 13,374 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001209191-21-036802 · doc4.xml · derivative · entry 8

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 13,374 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F6 · derivative.exercise_date: 1/3 of the shares subject to the Option vested on March 12, 2011 (the "March 2011 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the March 2011 Vesting Commencement Date over the following 4 years.

F5 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.

Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 12,345 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001209191-21-036802 · doc4.xml · derivative · entry 7

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 12,345 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F4 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "January 2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the January 2011 Vesting Commencement Date.

F5 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.

Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,912 $18.81 $54,774.72
Disclosure

SEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 6

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,232

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.22 to $19.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 3,155 $18.81 $59,345.55
Disclosure

SEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 5

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,144

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.22 to $19.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 2,192 $18.91 $41,450.72
Disclosure

SEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 4

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,299

F2 · price: Represents the closing price of the Company's common shares on May 27, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 13,374 $3.85 $51,489.90
Disclosure

SEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 3

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 2,024 $18.91 $38,273.84
Disclosure

SEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 2

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,117

F2 · price: Represents the closing price of the Company's common shares on May 27, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
May 28, 2021 Filed Jun 1, 2021 20:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 12,345 $3.76 $46,417.20
Disclosure

SEC source: 0001209191-21-036802 · doc4.xml · nonDerivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,141

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
March 12, 2021 Filed Mar 15, 2021 20:43 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $20.55 $0.00
Disclosure

SEC source: 0001209191-21-020481 · doc4.xml · derivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Shares · 65,000 shares

Expires 2031-03-11

F1 · derivative.exercise_date: Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
June 01, 2020 Filed Jun 2, 2020 21:40 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 8,230 $0.00 Strike: $3.56 $0.00
Disclosure

SEC source: 0001209191-20-033669 · doc4.xml · derivative · entry 3

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 8,230 shares

Expires 2020-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

F4 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.

Read SEC document
June 01, 2020 Filed Jun 2, 2020 21:40 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,630 $13.70 $22,331.00
Disclosure

SEC source: 0001209191-20-033669 · doc4.xml · nonDerivative · entry 2

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,796

F2 · price: Represents the closing price of the Company's common shares on May 29, 2020, which was converted to a Canadian dollar amount for purposes of net settlement calculations

Read SEC document
June 01, 2020 Filed Jun 2, 2020 21:40 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 8,230 $3.56 $29,298.80
Disclosure

SEC source: 0001209191-20-033669 · doc4.xml · nonDerivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

Read SEC document
March 12, 2020 Filed Mar 13, 2020 21:09 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $11.58 $0.00
Disclosure

SEC source: 0001209191-20-018963 · doc4.xml · derivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Shares · 65,000 shares

Expires 2030-03-11

F1 · derivative.exercise_date: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 23:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $9.44 $0.00
Disclosure

SEC source: 0001209191-19-050166 · doc4.xml · derivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Shares · 45,000 shares

Expires 2029-09-15

F1 · derivative.exercise_date: Vesting over 36 months, in equal amounts, on the last day of each month.

Read SEC document
September 12, 2019 Filed Sep 13, 2019 22:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 6,172 $0.00 Strike: $3.07 $0.00
Disclosure

SEC source: 0001209191-19-049538 · doc4.xml · derivative · entry 3

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 6,172 shares

Expires 2019-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document
September 12, 2019 Filed Sep 13, 2019 22:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,868 $9.38 $17,521.84
Disclosure

SEC source: 0001209191-19-049538 · doc4.xml · nonDerivative · entry 2

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,196

F2 · price: Represents the closing price of the Company's common shares on September 11, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
September 12, 2019 Filed Sep 13, 2019 22:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 6,172 $3.07 $18,948.04
Disclosure

SEC source: 0001209191-19-049538 · doc4.xml · nonDerivative · entry 1

ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,064

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

Read SEC document
March 15, 2018 Filed Mar 16, 2018 20:33 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 3,086 $0.00 Strike: $3.77 $0.00
Disclosure

SEC source: 0001171843-18-002049 · formfoursherrington.xml · derivative · entry 3

ROBIN SHERRINGTON · CIK 0001619962 · EVP Bus. & Corp. Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 3,086 shares

Expires 2018-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.